<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084603</url>
  </required_header>
  <id_info>
    <org_study_id>NICTDP1065/A6431116</org_study_id>
    <secondary_id>2008-006280-36</secondary_id>
    <nct_id>NCT01084603</nct_id>
  </id_info>
  <brief_title>Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product</brief_title>
  <official_title>Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product. A Study in Healthy Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of three products for oral nicotine replacement with respect to pharmacokinetics
      after single-dose of nicotine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares a new oral Nicotine Replacement Therapy (NRT) product with NiQuitin™
      lozenge 4 mg and Nicorette®gum 4 mg, after 12 hours of nicotine abstinence, with respect to
      nicotine pharmacokinetics, during 12 hours after start of administration. Single doses of
      each treatment are given once in the morning during five separate treatment visits scheduled
      in a crossover setting with randomized treatment sequences. The study will include 45 healthy
      smokers between 18-50 years, who have been smoking at least 15 cigarettes daily during at
      least one year preceding inclusion. Subjects and study personnel will be aware of which
      treatment is administered at a given visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>During 12 hours after start of administration</time_frame>
    <description>Cmax, which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered measured in nanograms/milliliter (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>12 hours</time_frame>
    <description>A measure of how much of the drug reaches a person's bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The area under the curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period to form a curve. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour*nanograms/milliliter (h*ng/ml).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nicotine Plasma Concentration</measure>
    <time_frame>During 10 minutes after start of administration</time_frame>
    <description>Area under the nicotine plasma concentration curve at 10 minutes (AUC10 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration</measure>
    <time_frame>During 12 hours after start of administration</time_frame>
    <description>The time at which maximum concentration is reached (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant</measure>
    <time_frame>During 12 hours after start of administration</time_frame>
    <description>The terminal nicotine elimination rate constant (Lamda z)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Released Nicotine</measure>
    <time_frame>After 30 minutes' chewing</time_frame>
    <description>The amount of nicotine released from Nicorette® gum 4 mg during 30 minutes' chewing</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Oral Nicotine 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One oral administration of 1 mg nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Nicotine 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two oral administrations of 1 mg nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Nicotine 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four oral administrations of 1 mg nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NiQuitinTM Nicotine Lozenge 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 4 mg marketed nicotine lozenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette® Gum 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Nicotine</intervention_name>
    <description>A new l mg oral nicotine product</description>
    <arm_group_label>Oral Nicotine 1</arm_group_label>
    <arm_group_label>Oral Nicotine 2</arm_group_label>
    <arm_group_label>Oral Nicotine 4</arm_group_label>
    <other_name>Experimental nicotine 1 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NiQuitinTM Nicotine Lozenge</intervention_name>
    <description>A marketed 4 mg Nicotine lozenge</description>
    <arm_group_label>NiQuitinTM Nicotine Lozenge 4 mg</arm_group_label>
    <other_name>NiQuitinTM lozenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorette® Nicotine Gum</intervention_name>
    <description>A marketed 4 mg Nicotine Gum</description>
    <arm_group_label>Nicorette® Gum 4 mg</arm_group_label>
    <other_name>Nicorette® gum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy smokers, smoking at least 15 cigarettes daily during at least one year
             preceding inclusion and BMI between 17.5 and 30.0 kg/m2.

          -  Female participants of child-bearing potential are required to use a medically
             acceptable means of birth control.

          -  A personally signed and dated informed consent document, indicating that the subject
             has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy.

          -  Treatment with an investigational product or donation or loss of blood within 3 months
             preceding the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology</name>
      <address>
        <city>Lund</city>
        <zip>222 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>April 16, 2010</results_first_submitted>
  <results_first_submitted_qc>June 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2010</results_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Full Safety Set</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>NiQuitinTM Lozenge</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Nicorette® Gum</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Oral Nicotine 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Oral Nicotine 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Oral Nicotine 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Full Safety Set</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration</title>
        <description>Cmax, which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered measured in nanograms/milliliter (ng/ml)</description>
        <time_frame>During 12 hours after start of administration</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 1</title>
            <description>1 administration of 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 2</title>
            <description>2 administrations of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 4</title>
            <description>4 administrations of 1 mg</description>
          </group>
          <group group_id="O4">
            <title>NiQuitinTM Lozenge 4 mg</title>
            <description>1 NiQuitinTM nicotine lozenge 4 mg</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration</title>
          <description>Cmax, which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered measured in nanograms/milliliter (ng/ml)</description>
          <population>ITT</population>
          <units>(ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="1.47"/>
                    <measurement group_id="O2" value="4.94" spread="2.06"/>
                    <measurement group_id="O3" value="8.63" spread="2.96"/>
                    <measurement group_id="O4" value="6.44" spread="2.06"/>
                    <measurement group_id="O5" value="7.36" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nicotine Plasma Concentration</title>
        <description>Area under the nicotine plasma concentration curve at 10 minutes (AUC10 min)</description>
        <time_frame>During 10 minutes after start of administration</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 1</title>
            <description>1 administration of 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 2</title>
            <description>2 administrations of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 4</title>
            <description>4 administrations of 1 mg</description>
          </group>
          <group group_id="O4">
            <title>NiQuitinTM Lozenge 4 mg</title>
            <description>1 NiQuitinTM nicotine lozenge 4 mg</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Nicotine Plasma Concentration</title>
          <description>Area under the nicotine plasma concentration curve at 10 minutes (AUC10 min)</description>
          <population>ITT</population>
          <units>(h*ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.23"/>
                    <measurement group_id="O2" value="0.56" spread="0.33"/>
                    <measurement group_id="O3" value="0.87" spread="0.42"/>
                    <measurement group_id="O4" value="0.29" spread="0.20"/>
                    <measurement group_id="O5" value="0.29" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Concentration</title>
        <description>The time at which maximum concentration is reached (Tmax)</description>
        <time_frame>During 12 hours after start of administration</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 1</title>
            <description>1 administration of 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 2</title>
            <description>2 administrations of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 4</title>
            <description>4 administrations of 1 mg</description>
          </group>
          <group group_id="O4">
            <title>NiQuitinTM Lozenge 4 mg</title>
            <description>1 NiQuitinTM nicotine lozenge 4 mg</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Concentration</title>
          <description>The time at which maximum concentration is reached (Tmax)</description>
          <population>ITT</population>
          <units>(hours)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.07" upper_limit="1.50"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.07" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.07" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.75" lower_limit="0.17" upper_limit="2.02"/>
                    <measurement group_id="O5" value="0.50" lower_limit="0.33" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant</title>
        <description>The terminal nicotine elimination rate constant (Lamda z)</description>
        <time_frame>During 12 hours after start of administration</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 1</title>
            <description>1 administration of 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 2</title>
            <description>2 administrations of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 4</title>
            <description>4 administrations of 1 mg</description>
          </group>
          <group group_id="O4">
            <title>NiQuitinTM Lozenge 4 mg</title>
            <description>1 NiQuitinTM nicotine lozenge 4 mg</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant</title>
          <description>The terminal nicotine elimination rate constant (Lamda z)</description>
          <population>ITT</population>
          <units>(1/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.13"/>
                    <measurement group_id="O2" value="0.29" spread="0.10"/>
                    <measurement group_id="O3" value="0.30" spread="0.10"/>
                    <measurement group_id="O4" value="0.26" spread="0.07"/>
                    <measurement group_id="O5" value="0.31" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Released Nicotine</title>
        <description>The amount of nicotine released from Nicorette® gum 4 mg during 30 minutes' chewing</description>
        <time_frame>After 30 minutes' chewing</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Nicorette® Gum 4 mg</title>
            <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Released Nicotine</title>
          <description>The amount of nicotine released from Nicorette® gum 4 mg during 30 minutes' chewing</description>
          <population>ITT</population>
          <units>(ng/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioavailability</title>
        <description>A measure of how much of the drug reaches a person’s bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The area under the curve (AUC) is calculated by plotting the drug’s blood levels on a graph at different times during the set period to form a curve. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour*nanograms/milliliter (h*ng/ml).</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 1</title>
            <description>1 administration of 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 2</title>
            <description>2 administrations of 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 4</title>
            <description>4 administrations of 1 mg</description>
          </group>
          <group group_id="O4">
            <title>NiQuitinTM Lozenge 4 mg</title>
            <description>1 NiQuitinTM nicotine lozenge 4 mg</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Bioavailability</title>
          <description>A measure of how much of the drug reaches a person’s bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The area under the curve (AUC) is calculated by plotting the drug’s blood levels on a graph at different times during the set period to form a curve. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour*nanograms/milliliter (h*ng/ml).</description>
          <units>h*ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC to last measurable concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" spread="3.7"/>
                    <measurement group_id="O2" value="11.50" spread="3.98"/>
                    <measurement group_id="O3" value="21.96" spread="9.00"/>
                    <measurement group_id="O4" value="22.00" spread="11.05"/>
                    <measurement group_id="O5" value="19.69" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC to infinity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.54" spread="4.10"/>
                    <measurement group_id="O2" value="13.30" spread="4.20"/>
                    <measurement group_id="O3" value="24.10" spread="9.35"/>
                    <measurement group_id="O4" value="24.30" spread="11.91"/>
                    <measurement group_id="O5" value="21.62" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Nicotine 1</title>
          <description>1 administration of 1 mg</description>
        </group>
        <group group_id="E2">
          <title>Oral Nicotine 2</title>
          <description>2 administrations of 1 mg</description>
        </group>
        <group group_id="E3">
          <title>Oral Nicotine 4</title>
          <description>4 administrations of 1 mg</description>
        </group>
        <group group_id="E4">
          <title>NiQuitinTM Lozenge 4 mg</title>
          <description>1 NiQuitinTM nicotine lozenge 4 mg</description>
        </group>
        <group group_id="E5">
          <title>Nicorette® Gum 4 mg</title>
          <description>One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 12.1">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joyce Hauze, Sr Specialist, Clinical Research Operations</name_or_title>
      <organization>J&amp;J Consumer and Personal Products Worldwide</organization>
      <phone>928-277-0715</phone>
      <email>jhauze@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

